Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

46.30 -13.48 (-22.54%)
Streaming Delayed Price Updated: 12:46 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 ↗
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
News headline image
Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
From Veracyte, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Pasithea Therapeutics (NASDAQ: 
Via Benzinga
News headline image
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
News headline image
63 Biggest Movers From Friday ↗
Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15... 
Via Benzinga
News headline image
Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
From Veracyte, Inc.
Via Business Wire
News headline image
Biotech Playbook 2021: No Help From Small Caps In Q4 ↗
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – December 1, 2021 – Early onset colorectal cancer is currently on the rise [[1]], according to a new study [[2]] from the... 
Via FinancialNewsMedia
News headline image
Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
From Veracyte, Inc.
Via Business Wire
News headline image
Looking for Growth in Small and Mid Cap Life Science Stocks ↗
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
News headline image
Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Third Quarter 2021 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 9, 2021 ↗
Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
News headline image
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
From Veracyte, Inc.
Via Business Wire
News headline image
New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
From Veracyte, Inc.
Via Business Wire
News headline image
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
News headline image
New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
From Veracyte, Inc.
Via Business Wire
News headline image
New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment
From Veracyte, Inc.
Via Business Wire
News headline image
New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease
From Veracyte, Inc.
Via Business Wire
News headline image
Is Veracyte Still a Buy After Its Recent Rally? ↗
Shares of the genetic diagnostics company are down nearly 50% from their 52-week high in February. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.